Das grundlegende hämatologische Produktportfolio von BeOne Medicines läutet auf der EHA 2026 eine neue Ära der Innovation bei B-Zell-Krebserkrankungen ein

Key Takeaway: BeOne Medicines is set to unveil its innovative hematological product portfolio at EHA 2026, focusing on advancements in B-cell malignancies. This event marks a significant moment for the company as it aims to introduce new solutions in the treatment landscape. The presentation is anticipated to attract attention from industry stakeholders and researchers alike.